Trial Profile
A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ARIEL2
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 19 Apr 2023 Results assessing the predictive value retrospectively as a biomarker for rucaparib benefit in the ARIEL2 study, presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 01 May 2022 Results of population pharmacokinetics model Study 1014 (NCT01009190), Study 10 (NCT01482715), and ARIEL2 (NCT01891344) published in the Cancer Chemotherapy and Pharmacology
- 31 Jan 2022 Status changed from active, no longer recruiting to completed.